Company
Biogen Inc
NASDAQ:BIIB
Biogen Inc is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich’s ataxia.
60 stories · page 1 of 3
Archive
Fuller Treacy Comment of the Day - Ford Takes $3.6 Billion Hit for Following the Tesla Playbook, and more...
Comment of the Day18th July 2023Eoin TreacyJul 19Video commentary for July 18th 2023A link to today's video commentary is posted in the Subscriber's Area.Some of the topics discussed include: US banks rebound, Dow Industrials and Transporta
Biogen shares fall on 4Q results but Canaccord analysts remain optimistic about Alzheimer's drug
The company expects sales to decline by mid-single digit percentages in 2023 after they fell nearly 7% to $2.54 billion in the fourth quarter
Roche Alzheimer's failure good news for rivals, analysts suggest
Roche said while there had been some level of beta-amyloid removal it was lower than expected
Biogen and Alzheimer's drug development companies surge on positive clinical data
Biogen surged 35% to US$267.80 in the five days to Friday following the news
Archive
US stocks lose steam at the close, Dow's winning streak ends
The S&P 500 lost 0.30% to sit at 4,779 points while the Dow sank 0.25% to finish at 36,398 points and the Nasdaq closed at 15,742 points for a 0.16% retreat on the day
FDA officials should resign over 'reckless' approval of Biogen Alzheimer’s drug, says US consumer rights group
Special interest group Public Citizen said in an open letter that the FDA should have rejected the drug and that its surprise approval "raised false hope for millions of Alzheimer’s disease patients"
Biogen's hefty price tag for new drug forecast to spark Alzheimer's research resurgence
News of the approval gave a boost to other companies developing Alzheimer’s treatments
Investments and investor services
Tiziana Life Sciences: US investment bank restates its US$8 price and 'buy' recommendation after double dose of good news
“Despite a recent pullback in the shares…we continue to like the risk-reward set-up," said B Riley Financial in a note to clients
Biogen to produce first therapy for Alzheimer’s if FDA approves next year
Aducanumab aims at reducing the clinical decline of the disease rather than the underlying cause